BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34856395)

  • 1. Focal adhesion kinase inhibitors in the treatment of solid tumors: Preclinical and clinical evidence.
    Quispe PA; Lavecchia MJ; León IE
    Drug Discov Today; 2022 Feb; 27(2):664-674. PubMed ID: 34856395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Focal adhesion kinase-An emerging viable target in cancer and development of focal adhesion kinase inhibitors.
    Chauhan A; Khan T
    Chem Biol Drug Des; 2021 Mar; 97(3):774-794. PubMed ID: 33191630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal adhesion kinase as a cancer therapy target.
    Golubovskaya VM
    Anticancer Agents Med Chem; 2010 Dec; 10(10):735-41. PubMed ID: 21214510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.
    Stone RL; Baggerly KA; Armaiz-Pena GN; Kang Y; Sanguino AM; Thanapprapasr D; Dalton HJ; Bottsford-Miller J; Zand B; Akbani R; Diao L; Nick AM; DeGeest K; Lopez-Berestein G; Coleman RL; Lutgendorf S; Sood AK
    Cancer Biol Ther; 2014 Jul; 15(7):919-29. PubMed ID: 24755674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders.
    Yang M; Xiang H; Luo G
    Biochem Pharmacol; 2024 Jun; 224():116246. PubMed ID: 38685282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Pathways: Endothelial Cell FAK-A Target for Cancer Treatment.
    Roy-Luzarraga M; Hodivala-Dilke K
    Clin Cancer Res; 2016 Aug; 22(15):3718-24. PubMed ID: 27262114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The roles of nuclear focal adhesion kinase (FAK) on Cancer: a focused review.
    Zhou J; Yi Q; Tang L
    J Exp Clin Cancer Res; 2019 Jun; 38(1):250. PubMed ID: 31186061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting focal adhesion kinase in neuroblastoma.
    Gillory L; Beierle EA
    Anticancer Agents Med Chem; 2010 Dec; 10(10):714-21. PubMed ID: 21269252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors.
    Marlowe TA; Lenzo FL; Figel SA; Grapes AT; Cance WG
    Mol Cancer Ther; 2016 Dec; 15(12):3028-3039. PubMed ID: 27638858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review.
    Shanthi E; Krishna MH; Arunesh GM; Venkateswara Reddy K; Sooriya Kumar J; Viswanadhan VN
    Expert Opin Ther Pat; 2014 Oct; 24(10):1077-100. PubMed ID: 25113248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment.
    Wu X; Wang J; Liang Q; Tong R; Huang J; Yang X; Xu Y; Wang W; Sun M; Shi J
    Biomed Pharmacother; 2022 Jul; 151():113116. PubMed ID: 35598365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK).
    Lu Y; Sun H
    J Med Chem; 2020 Dec; 63(23):14382-14403. PubMed ID: 33058670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights.
    Yoon H; Dehart JP; Murphy JM; Lim ST
    J Histochem Cytochem; 2015 Feb; 63(2):114-28. PubMed ID: 25380750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials.
    Mohanty A; Pharaon RR; Nam A; Salgia S; Kulkarni P; Massarelli E
    Expert Opin Investig Drugs; 2020 Apr; 29(4):399-409. PubMed ID: 32178538
    [No Abstract]   [Full Text] [Related]  

  • 15. Signal transduction by focal adhesion kinase in cancer.
    Zhao J; Guan JL
    Cancer Metastasis Rev; 2009 Jun; 28(1-2):35-49. PubMed ID: 19169797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Insights on Fak and Fak Inhibitors.
    Brullo C; Tasso B
    Curr Med Chem; 2021; 28(17):3318-3338. PubMed ID: 33143618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FAK signaling in human cancer as a target for therapeutics.
    Lee BY; Timpson P; Horvath LG; Daly RJ
    Pharmacol Ther; 2015 Feb; 146():132-49. PubMed ID: 25316657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging roles of focal adhesion kinase in cancer.
    Tai YL; Chen LC; Shen TL
    Biomed Res Int; 2015; 2015():690690. PubMed ID: 25918719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer.
    Peng K; Zhang F; Wang Y; Sahgal P; Li T; Zhou J; Liang X; Zhang Y; Sethi N; Liu T; Zhang H; Bass AJ
    Clin Cancer Res; 2023 Jan; 29(1):197-208. PubMed ID: 36278961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Advances of Small Molecule Focal Adhesion Kinase (FAK) Inhibitors as Promising Anticancer Therapeutics.
    Lv P; Chen K; Zhu HL
    Curr Med Chem; 2021 Oct; 28(34):6977-6989. PubMed ID: 33797359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.